Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPA-SWEET: Dapagliflozin Effects in High CV Risk
NCT04258371Phase 2Unknown
- Sponsor
- University Health Network
- Start
- Feb 2020
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dapagliflozin in cardiovascular diseases (CVD), sponsored by University Health Network. Status: unknown.
02
Drugs
dapagliflozin
03
Conditions
cardiovascular diseases (CVD)
Beyond the preview
Go deeper on NCT04258371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04258371.